'Dual hit' metabolic modulator LDCA selectively kills cancer cells by efficient competitive inhibition of LDH-A

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Lactate dehydrogenase isoform-A (LDH-A) plays a critical role in cancer cell metabolism and survival.
• Targeting cancer metabolism is a promising strategy for developing novel anti-cancer therapies.
• Dysregulation of LDH-A is implicated in the progression of various cancers, including breast cancer.

Purpose of the Study:

• To synthesize and characterize a novel 'dual hit' molecule, LDCA.
• To investigate the potential of LDCA to constitutively block LDH-A.
• To evaluate the efficacy of LDCA in subverting apoptosis and attenuating breast tumor progression in a preclinical mouse model.

Main Methods:

• Synthesis and characterization of the LDCA molecule.
• In vitro assays to assess LDH-A inhibition and apoptosis.
• In vivo studies using a mouse model of breast cancer to evaluate tumor progression and therapeutic effects.

Main Results:

• Successful synthesis and validation of the LDCA molecule.
• LDCA demonstrated constitutive blockade of LDH-A.
• LDCA selectively subverted apoptosis and significantly attenuated breast tumor progression in the mouse model.
• The study comprehensively delineated the therapeutic prospectus of LDCA in cancer metabolics.

Conclusions:

• LDCA represents a novel therapeutic agent with the potential to target cancer metabolism.
• Constitutive inhibition of LDH-A by LDCA offers a promising strategy for breast cancer treatment.
• Further investigation into LDCA is warranted to explore its clinical applications in oncology.